A Phase 3, Randomized, Open-Label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered In Combination With Reduced-Intensity Chemotherapy, In Patients With Actively Diagnosed Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Read more
A Phase 3, Open-Label, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (ACE-536) Versus Epoetin Alfa For The Treatment Of Anemia Due To IPSS-R Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes (MDS) In ESA Naïve Subjects Who Require Red Blood Cell Transfusions Read more
Connect MDS And AML: The Myelodysplastic Syndromes (MDS) And Acute Myeloid Leukemia (AML) Disease Registry Read more
A Phase 1 Trial To Evaluate The Potential Impact Of Renal Impairment On The Pharmacokinetics And Safety Of CPX-351 (Daunorubicin And Cytarabine) Liposome For Injection Treatment In Adult Patients With Hematologic Malignancies Read more
Abbvie, Protocol: M16-191, PI: Dr. Mccloskey, Title A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1) Read more
Abbvie, Protocol: M20-178, PI: Dr. Mccloskey, A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy And Safety Of Navitoclax In Combination With Ruxolitinib Versus Best Available Therapy In Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) Read more
A Multi-Phase, Dose-Escalation Followed By An Open-Label, Randomized, Crossover Study Of Oral ASTX030 (Cedazuridine And Azacitidine Given In Combination) Versus Subcutaneous Azacitidine In Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Or Acute Myeloid Leukemia (AML) Read more
An Open-Label, Multicenter, Extension Study For Subjects Who Participated In Prior Clinical Studies Of ASTX727 (Standard Dose) Read more
